Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArriVent BioPharmaAVBP -3.27%12 Current Ratio is 13.95 as of Mar. 2026, which is 5% below its 10-year median of 14.62. GuruFocus rates AVBP with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, ArriVent BioPharma ranks better than 85.19% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ArriVent BioPharma's current ratio for the quarter that ended in Mar. 2026 was 13.95.
ArriVent BioPharma has a current ratio of 13.95. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for ArriVent BioPharma's Current Ratio or its related term are showing as below:
AVBP'
s Current Ratio Range Over the Past 10 Years
Min: 12.74 Med: 14.62 Max: 32.82
Current: 13.95
During the past 5 years, ArriVent BioPharma's highest Current Ratio was 32.82. The lowest was 12.74. And the median was 14.62.
AVBP's Current Ratio is ranked better than 85.19% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs AVBP: 13.95
ArriVent BioPharma (NAS:AVBP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
ArriVent BioPharma Current Ratio Related Terms
ArriVent BioPharma Current Ratio Historical Data
* Premium members only.
The historical data trend for ArriVent BioPharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVBP vs MAZE, DMRA, AKTS: Current Ratio Comparison
For the Biotechnology subindustry, ArriVent BioPharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArriVent BioPharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where ArriVent BioPharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ArriVent BioPharma (AVBP) has a Current Ratio of 13.95 as of Mar. 2026. This is near median its historical median of 14.62. Over the past decade, ArriVent BioPharma's Current Ratio has ranged from 12.74 to 32.82. According to the industry distribution chart, ArriVent BioPharma ranks #209 out of 1411 companies in the Biotechnology industry, placing it in the top 14.8%.
Is ArriVent BioPharma's Current Ratio too high?
ArriVent BioPharma's current Current Ratio of 13.95 is near median its 10-year median of 14.62. Over the past 10 years, this metric has ranged from a low of 12.74 to a high of 32.82. The Biotechnology industry median Current Ratio is 3.88. ArriVent BioPharma's value of 13.95 is 259.5% above this industry median. Based on the distribution chart, ArriVent BioPharma ranks #209 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ArriVent BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does ArriVent BioPharma's Current Ratio compare to MAZE and DMRA?
According to the Biotechnology industry distribution chart, ArriVent BioPharma ranks #209 out of 1411 companies for Current Ratio. This places ArriVent BioPharma in the top 15% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. ArriVent BioPharma's value of 13.95 is 259.5% above this benchmark. Historically, ArriVent BioPharma's own Current Ratio has ranged from 12.74 to 32.82 over the past decade. While the company's 10-year median is 14.62 vs. the industry median of 3.88, ArriVent BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ArriVent BioPharma's current Current Ratio of 13.95 is 259.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ArriVent BioPharma's current Current Ratio is 13.95, which is near median its own 10-year median of 14.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArriVent BioPharma stock overvalued right now?
ArriVent BioPharma (AVBP) has a current Current Ratio of 13.95. The current Current Ratio is 13.95, which is near median its 10-year median of 14.62 and 259.5% above the Biotechnology industry median of 3.88. ArriVent BioPharma's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For ArriVent BioPharma (AVBP), the current Current Ratio is 13.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
12GF Score
Get the complete analysis for AVBP
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVBP has been successfully added to your 
